A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests. A ...

OXGENE™ and The Native Antigen Company today announced a collaboration to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology ...

Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19 SASKATOON, ...

RNA vaccine technology has emerged as a groundbreaking approach in the field of immunology and infectious disease prevention.

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the third installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic ...

Co announces that its Viral Antigens production facility, located in Memphis, TN recently received USDA/APHIS EC 1774:2002 approval. This important regulatory approval, for one of the largest viral ...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. ("ZYUS"), a company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and ...